Analysts Have Conflicting Sentiments on These Healthcare Companies: Immunome (IMNM), Hinge Health, Inc. Class A (HNGE) and Stryker (SYK)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Immunome (IMNM – Research Report), Hinge Health, Inc. Class A (HNGE – Research Report) and Stryker (SYK – Research Report).
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Immunome (IMNM)
Truist Financial analyst Karina Rabayeva maintained a Buy rating on Immunome today. The company’s shares closed last Wednesday at $22.52.
Rabayeva has an average return of
According to TipRanks.com, Rabayeva is ranked #11008 out of 12134 analysts.
Immunome has an analyst consensus of Strong Buy, with a price target consensus of $35.73, which is a 62.4% upside from current levels. In a report issued on March 3, LifeSci Capital also maintained a Buy rating on the stock with a $40.00 price target.
See today’s best-performing stocks on TipRanks >>
Hinge Health, Inc. Class A (HNGE)
Truist Financial analyst Jailendra Singh maintained a Buy rating on Hinge Health, Inc. Class A today. The company’s shares closed last Wednesday at $45.71.
According to TipRanks.com, Singh is ranked 0 out of 5 stars with an average return of
Currently, the analyst consensus on Hinge Health, Inc. Class A is a Strong Buy with an average price target of $59.08, a 31.3% upside from current levels. In a report issued on February 27, Stifel Nicolaus also maintained a Buy rating on the stock with a $59.00 price target.
Stryker (SYK)
In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Stryker. The company’s shares closed last Wednesday at $381.89.
According to TipRanks.com, Newitter is a 5-star analyst with an average return of
Currently, the analyst consensus on Stryker is a Strong Buy with an average price target of $431.17, a 12.6% upside from current levels. In a report issued on February 24, UBS also maintained a Hold rating on the stock with a $400.00 price target.
